CleanSpark (CLSK) Is Down 5.2% After Weaker Earnings Outlook Ahead of August Report Has The Bull Case Changed?

• CleanSpark recently saw its shares fall over the past week as investors responded to ongoing concerns about financial challenges and an upcoming earnings release originally scheduled for August 6, 2026.
• Analysts now expect meaningful year-over-year declines in both earnings and revenue, highlighting persistent profitability pressures despite earlier optimism about the company’s operating efficiency and market position.
• Next, we’ll examine how these weaker earnings expectations ahead of the report interact with CleanSpark’s existing investment narrative and risk profile.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

CleanSpark Investment Narrative Recap

To stay invested in CleanSpark right now, you need to believe that its Bitcoin mining scale, energy efficiency, and new infrastructure deals can eventually support improving financial results, despite current losses. The recent share pullback and weaker earnings expectations underscore that the near term catalyst is the August 6 earnings report, while the biggest risk remains ongoing profitability pressure if Bitcoin economics and operating costs do not improve. This news reinforces existing concerns but does not fundamentally change that risk.

The most relevant recent announcement is CleanSpark’s 20 year infrastructure lease in Sandersville, Georgia, with expected contracted revenue of about US$6,600 million over the initial term. While this agreement highlights a potential shift toward steadier, lease based income that could complement volatile mining revenue, investors will likely weigh it against the upcoming earnings release and the company’s history of large net losses when assessing how quickly it might affect the overall risk and catalyst profile.

Yet beneath the appeal of long term contracts, investors should be aware of how rising energy costs and shifting policies could still...

Read the full narrative on CleanSpark (it's free!)

CleanSpark's narrative projects $918.5 million revenue and $111.2 million earnings by 2029. This requires 7.5% yearly revenue growth and a $647.8 million earnings increase from -$536.6 million today.

Uncover how CleanSpark's forecasts yield a $21.12 fair value, a 53% upside to its current price.

Exploring Other Perspectives

You can see how wide opinions run here: the most pessimistic analysts were already assuming revenue could shrink about 9.9% a year and still needed earnings of roughly US$64.8 million by 2029 to justify their lower price targets, which is a far harsher lens on CleanSpark’s risk than the consensus view and may look very different again after this latest earnings scare.

Explore 6 other fair value estimates on CleanSpark - why the stock might be worth as much as 89% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your CleanSpark research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free CleanSpark research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CleanSpark's overall financial health at a glance.

Looking For Alternative Opportunities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com